Targeted cancer therapies based on molecular markers such as endocrine therapy for prostate cancer or inhibiting ER activity in ER-positive breast cancer also benefits from a multimodal treatment approach that can include endocrine based therapies, along with chemotherapy involving single or multiple cytotoxic agents [19, 20, 49–53]. This evidence concerns the gene ESR1 and cancer.